We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+42.24%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.31B
AUM Growth
+$640M
Cap. Flow
+$115M
Cap. Flow %
4.97%
Top 10 Hldgs %
73.01%
Holding
40
New
6
Increased
6
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$46.1M
2
AMRN
Amarin Corp
AMRN
+$43.7M
3
ARRY
Array Biopharma Inc
ARRY
+$41.6M
4
MDCO
Medicines Co
MDCO
+$36.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$63.6M
2
LOXO
Loxo Oncology, Inc
LOXO
+$45.5M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.2M
4
TGTX icon
TG Therapeutics
TGTX
+$19.5M
5
ASND icon
Ascendis Pharma A/S
ASND
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$340M 14.71%
17,714,461
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$283M 12.24%
3,862,500
-935,601
-19% -$63.6M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$211M 9.14%
1,795,000
-185,000
-9% -$16.2M
AMRN
4
Amarin Corp
AMRN
$300M
$166M 7.18%
400,000
+121,250
+43% +$43.7M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$142M 6.16%
1,195,000
-80,000
-6% -$10.3M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$129M 5.59%
9,500,000
-625,000
-6% -$7.63M
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$106M 4.57%
4,000,000
-350,000
-8% -$8.29M
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$105M 4.56%
1,915,000
-60,000
-3% -$2.85M
ARGX icon
9
argenx
ARGX
$54.8B
$105M 4.53%
840,000
-20,000
-2% -$2.35M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.03B
$100M 4.33%
10,530,862
+269,823
+3% +$2.62M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.9B
$99.5M 4.3%
1,120,000
-240,000
-18% -$22.2M
TCDA
12
DELISTED
Tricida, Inc. Common Stock
TCDA
$65.7M 2.84%
1,700,000
-50,000
-3% -$1.16M
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$52M 2.25%
+1,000,000
New +$46.1M
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
$50.3M 2.17%
950,000
+600,000
+171% +$29.5M
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
$48.8M 2.11%
+2,000,000
New +$41.6M
MDCO
16
DELISTED
Medicines Co
MDCO
$43.7M 1.89%
+1,562,000
New +$36.8M
BDSI
17
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$39.4M 1.7%
7,424,867
+2,699,867
+57% +$12.3M
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.4B
$38.8M 1.68%
310,000
+85,000
+38% +$10.6M
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.45B
$35.6M 1.54%
+1,325,000
New +$30.9M
ALLO icon
20
Allogene Therapeutics
ALLO
$607M
$29.8M 1.29%
1,128,594
+10
+0% +$290
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.16B
$24.4M 1.05%
2,400,000
– –
INDP icon
22
Indaptus Therapeutics
INDP
$254M
$18.3M 0.79%
1,116
– –
ASMB icon
23
Assembly Biosciences
ASMB
$494M
$17.7M 0.77%
75,000
-8,333
-10% -$2.11M
PCRX icon
24
Pacira BioSciences
PCRX
$1.04B
$15.2M 0.66%
400,000
– –
ESTA icon
25
Establishment Labs
ESTA
$2.67B
$11.4M 0.49%
475,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Avoro Capital Advisors held 40 positions worth $2.31B, up 38% from $1.67B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $115M of net new capital in Q1 2019, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was MyoKardia, Inc. Common Stock: 1,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $63.6M trimmed.

  • Avoro Capital Advisors's largest Q1 2019 buy was MyoKardia, Inc. Common Stock: 1,000,000 shares worth $52M.
  • Avoro Capital Advisors added most to Amarin Corp in Q1 2019, an estimated $43.7M increase.
  • Avoro Capital Advisors's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $63.6M.
  • Avoro Capital Advisors fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $45.5M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $2.31B portfolio in Q1 2019.
  • Avoro Capital Advisors opened 6 new positions and closed 8 in Q1 2019.
  • Avoro Capital Advisors's portfolio value rose 38% quarter-over-quarter to $2.31B.

Based on Avoro Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.